Amyloidosis and TAVR: Does this Disease Have an Impact?

Amyloidosis is a systemic disease that affects different organs and impairs their function.

Amiloidosis y TAVI: ¿tiene impacto esta enfermedad?

Recent studies with magnetic resonance imaging (MRI) have shown that between 13% and 16% of patients who undergo transcatheter aortic valve replacement (TAVR) have amyloidosis. 

A review of four studies showed that mortality at 20 months was twice as high when amyloidosis was present after device implantation. However, other more recent studies show no difference in mortality.

Researchers analyzed the US NRD (Nationwide Readmissions Database) from January 2016 to December 2019 and included 244,967 hospitalizations for TAVR. Among these cases, 273 patients had amyloidosis (0.11%).

Mean age was 79 years and most subjects were female. There was a greater presence of atrial fibrillation and impaired renal function. However, these patients also exhibited lower levels of hypertension, diabetes, and MRS.

There were no differences in in-hospital mortality or 30-day readmissions (1.8% vs. 1.5%, p = 0.622; and 12.9% vs. 12.5%, p = 0.858; respectively). The rate of acute ischemic stroke was higher in patients with amyloidosis (6.2% vs. 1.8%, p < 0.001), and so was the rate of acute ischemic and hemorrhagic stroke (7.2% vs. 1.8%, p < 0.001).

Read also: TriClip: Tricuspid Regurgitation Dedicated Device.

A propensity score was estimated by logistic regression and results showed that the group with amyloidosis was associated with a higher risk of acute ischemic stroke (odds ratio [OR] 3.08; 95% confidence interval [CI]: 1.41-6.71; p = 0.005), but there were no differences in mortality (OR: 0.79; 95% CI: 0.28-2.27, p = 0.666) and 30-day readmissions (hazard ratio: 0.72; 95% CI: 0.41-1.25; p = 0.241) in TAVI.

Conclusion

This analysis suggests that amyloidosis may be associated with a higher risk of thromboembolism after TAVR. However, these data warrant further investigation.

Dr. Carlos Fava - Consejo Editorial SOLACI

Dr. Carlos Fava.
Member of the Editorial Board of SOLACI.org.

Original Title: Outcomes of Transcatheter Aortic Valve Replacement in Patients With Coexisiting Amyloidosis. Mortality, Stroke, and Readmission.

Reference: Mohammed Elzeneini, et al JACC Adv 2023;-:100255 Article in press.


Subscribe to our weekly newsletter

Get the latest scientific articles on interventional cardiology

More articles by this author

ACC 2025 | TAVI in Low-Risk Patients: 5-Year Outcomes of EVOLUTE LOW RISK

Transcatheter aortic valve implantation (TAVI) is a valid alternative to surgery in low-risk patients with severe aortic stenosis. However, one of its main limitations...

ACC 2025 | BHF PROTECT-TAVI: Are Cerebral Protection Systems Necessary in TAVI?

TAVI has seen a steady increase in use, though stroke continues to be one of its unwanted complications, mostly ischemic and, less frequently, hemorrhagic. The...

ACC-2025 Congress Second Day Key Studies

BHF PROTECT-TAVI (Kharbanda RK, Kennedy J, Dodd M, et al.)The largest randomized  trial carried out across 33 UK centers between 2020 and 2024, assessing...

Prospective Analysis of the Feasibility of the PASCAL System for Transcatheter Mitral Repair: OneForAll Registry

Courtesy of Dr. Juan Manuel Pérez. Mitral transcatheter edge-to-edge repair (M-TEER) is an effective option for patients with severe mitral regurgitation who are at high...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

SOLACI Sessionsspot_img

Recent Articles

Patients at High Risk of Bleeding After Coronary Angioplasty: Are Risk Assessment Tools ARC-HBR and PRECISE-DAPT Useful?

Patients undergoing coronary stenting typically receive dual antiplatelet therapy (DAPT) for 6 to 12 months, consisting of a P2Y12 receptor inhibitor and aspirin. While DAPT...

ACC 2025 | WARRIOR: Ischemia in Women with Non-Obstructive Coronary Artery Disease

Approximately half of all women with symptomatic ischemia who undergo coronary angiography are found to have non-obstructive coronary artery disease ((ischemia and non-obstructive coronary...

ACC 2025 | TAVI in Low-Risk Patients: 5-Year Outcomes of EVOLUTE LOW RISK

Transcatheter aortic valve implantation (TAVI) is a valid alternative to surgery in low-risk patients with severe aortic stenosis. However, one of its main limitations...